Tomasz Skoczylas

Lublin, LU, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 30 publications

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.

Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 24, 2025

The usefulness and effectiveness of interactive telemedicine in surgery classes - a survey of Polish medical students.

The usefulness and effectiveness of interactive telemedicine in surgery classes - a survey of Polish medical students.

Journal: Polski przeglad chirurgiczny

Published: August 14, 2024

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Nivolumab plus chemotherapy or ipilimumab in gastroesophageal cancer: exploratory biomarker analyses of a randomized phase 3 trial.

Journal: Nature medicine

Published: May 08, 2024

ApoA-I and ApoB levels, and ApoB-to-ApoA-I ratio as candidate pre-treatment biomarkers of pathomorphological response to neoadjuvant therapy in gastric and esophago-gastric junction adenocarcinoma.

ApoA-I and ApoB levels, and ApoB-to-ApoA-I ratio as candidate pre-treatment biomarkers of pathomorphological response to neoadjuvant therapy in gastric and esophago-gastric junction adenocarcinoma.

Journal: Polski przeglad chirurgiczny

Published: April 17, 2024

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

First-Line Nivolumab Plus Chemotherapy for Advanced Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma: 3-Year Follow-Up of the Phase III CheckMate 649 Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 21, 2024

Influence of Clinical Factors on miR-3613-3p Expression in Colorectal Cancer.

Influence of Clinical Factors on miR-3613-3p Expression in Colorectal Cancer.

Journal: International journal of molecular sciences

Published: August 01, 2023

Corrigendum to "Dissecting the genetic heterogeneity of gastric cancer".

Corrigendum to "Dissecting the genetic heterogeneity of gastric cancer".

Journal: EBioMedicine

Published: July 22, 2023

A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.

A plain language summary of the CheckMate 649 study: nivolumab in combination with chemotherapy compared to chemotherapy alone for untreated advanced or metastatic cancer of the stomach or esophagus.

Journal: Future oncology (London, England)

Published: March 15, 2023

Dissecting the genetic heterogeneity of gastric cancer.

Dissecting the genetic heterogeneity of gastric cancer.

Journal: EBioMedicine

Published: December 21, 2022

Polish Consensus on Gastric Cancer Diagnosis and Treatment - Update 2022.

Polish Consensus on Gastric Cancer Diagnosis and Treatment - Update 2022.

Journal: Polski przeglad chirurgiczny

Published: September 01, 2022

Pre-therapeutic molecular biomarkers of pathological response to neoadjuvant chemotherapy in gastric and esophago-gastric junction adenocarcinoma: A systematic review and meta-analysis.

Pre-therapeutic molecular biomarkers of pathological response to neoadjuvant chemotherapy in gastric and esophago-gastric junction adenocarcinoma: A systematic review and meta-analysis.

Journal: Advances in medical sciences

Published: July 10, 2022

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.

Nivolumab plus chemotherapy or ipilimumab in gastro-oesophageal cancer.

Journal: Nature

Published: October 22, 2021

Showing 1-12 of 30

Last Updated: 09/26/2026